/
Oncology
Solid Tumor
456
Pipeline Programs↗
520
Active Trials↗
278
Companies Involved↗
Solid Tumor is a highly competitive landscape with 456 programs across 278 companies. The most active players are Roche, Merck & Co., Daiichi Sankyo. 12 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical140
Phase 1235
Phase 269
Phase 312
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
293 of 353 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 353 classified programs, each share of the total. Modality classified for 84% of 456 pipeline programs.
Analysis
Trial Status
776
clinical trials
Recruiting333 · 43%
Completed167 · 22%
Active, not recruiting111 · 14%
Not yet recruiting69 · 9%
Terminated52 · 7%
Unknown status18 · 2%
Other26 · 3%
Clinical Trials
Trial Activity
776 trials
An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors
Recruiting·—·Phase 1·NCT05856981·130 enrolled
Page 1 of 52
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)